
Athira Pharma, Inc.
- Jurisdiction
United States - LEI
529900CSS4S4X8VY5C81 - ISIN
US04746L1044 (ATHA )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Read full profile
Stock price
Fundamentals
- Net revenue
€0.00 - Gross margin
0.0% - EBIT
-€52.89M - EBIT margin
0.0% - Net income
-€51.05M - Net margin
0.0%
Statement period: - (published )
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: March 24, 2022
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Buy |